Please login to the form below

Not currently logged in
Email:
Password:

Gilead agrees HIV patent pool deal

Gilead Sciences has become the first pharmaceutical company to agree to improve access to HIV and hepatitis B treatments in developing countries by signing a deal with the Medicines Patent Pool

Gilead Sciences has become the first pharmaceutical company to agree to improve access to HIV and hepatitis B treatments in developing countries  by signing a deal with the Medicines Patent Pool.

The Pool negotiates with patent holders to share their intellectual property with the Pool, and then licenses it to other producers to facilitate the production of affordable generic medicines for use in resource-poor settings.

This includes developing medicines that do not require refrigeration (with electricity a large issue in many areas) or are 'fixed-dose combinations' that combine multiple medicines into one pill for ease of treatment.

Gilead's agreement will see the Pool make use of Gilead's intellectual property for the HIV medicines tenofovir, emtricitabine, cobicistat, and elvitegravi to produce versions of these medicines, as well as a combination pill to be called Quad.

The licence also allows for the development and manufacture of other combinations that include these medicines, with Tenofovir also licensed for use in hepatitis B.

"The licence agreement with Gilead Sciences will help make medicines available at a lower-cost and in easier to use formulations without delays," said Ellen 't Hoen, executive director of the Pool.

"People in developing countries often have to wait for years before they can access new health technologies. Today's agreement changed that."

Gregg Alton, executive vice president, corporate and medical affairs for Gilead Sciences, also commented on the agreement: "We are pleased to enter into this collaboration, and we hope to see the Pool become an effective mechanism for providing access to an increasingly broader range of antiretrovirals to treat HIV in resource-limited parts of the world."

12th July 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics